Top

Irish Journal of Medical Science (1971 -)

Published in:

01-08-2019 | Original Article

The role of increased synovial fluid A disintegrin and metalloproteinase with thrombospondin motifs4 and serglycin levels in osteoarthritis

Author: kenan ÖZLER

Published in: Irish Journal of Medical Science (1971 -) | Issue 3/2019

Abstract

Background

The first research to determine synovial fluid ADAMTS4 and serglycin levels in osteoarthritis and OA progression.

Aim

We aimed to determine ADAMTS4 and serglycin levels, interactions, and changes in the synovial fluid of knee OA, and also to determine effective in OA progression.

Methods

A case-control study was carried out including a total of 88 participants (29 patients late OA [LOA], 28 early OA [EOA], and 30 controls). Synovial fluid serglycin and ADAMTS4 levels were measured by commercially available ELISA kits, and knee functions of the patients were evaluated with The Western Ontario and McMaster Universities Osteoarthritis score (WOMAC). Logistic regression analysis was applied for the associated with progression of OA.

Results

Synovial fluid ADAMTS4 and serglycin levels were significantly higher in LOA than EOA and control groups (p < .001 and p < .001; p = .038 and p = .007, respectively). All parameters were evaluated after adjustment for age. LOA patients had significantly higher levels of WOMAC score than EOA and controls (p < .001 and p < .001). According to the logistic regression analysis, synovial fluid ADAMTS4, serglycin levels, and WOMAC score were found to be significantly associated with progression of OA.

Dillon CF, Rasch EK, Gu Q et al (2006) Prevalence of knee osteoarthritis in the United States: arthritis data from thethird national health and nutrition examination survey 1991–94. J Rheumatol 33(11):2271–2279PubMed

Maroudas A (1976) Balance between swelling pressure and collagen tension in normal and degenerate cartilage. Nature (London) 260:808–809CrossRef

Song RH, Tortorella MD, Malfait AM et al (2007) Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 56:575–585CrossRefPubMed

Arner EC (2002) Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol 2:322–329CrossRefPubMed

Yaykasli KO, Hatipoglu OF, Yaykasli E et al (2015) Leptin induces ADAMTS-4, ADAMTS-5, and ADAMTS-9 genes expression by mitogen-activated protein kinases and NF-ĸB signaling pathways in human chondrocytes. Cell Biol Int 39(1):104–112. https://doi.org/10.1002/cbin.10336 CrossRefPubMed

Malfait AM, Liu RQ, Ijiri K, Komiya S, Tortorella MD (2002) Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 277:22201–22208CrossRefPubMed

Scully OJ, Chua PJ, Harve KS, Bay BH, Yip GW (2012) Serglycin in health and diseases. Anat Rec (Hoboken) 295(9):1415–1420. https://doi.org/10.1002/ar.22536 CrossRef

Schick BP, Gradowski JF, San Antonio JD (2001) Synthesis, secretion, and subcellular localization of serglycin proteoglycan in human endothelial cells. Blood 97(2):449–458CrossRefPubMed

Omtvedt LA, Kolset SO, Thoen J, Førre Y, Gill MR (2001) Serglycin expression in CD2+ and CD14+ cells from patients with various rheumatic diseases. Scand J Rheumatol 30(3):164–166CrossRefPubMed

10.

Zhang L, Yang M, Yang D, Cavey G, Davidson P, Gibson G (2010) Molecular interactions of MMP-13 C-terminal domain with chondrocyte proteins. Connect Tissue Res 51(3):230–239. https://doi.org/10.3109/03008200903288902 CrossRefPubMed

11.

Kellgren JH, Lawrence JS (1957) Radiological assessment of osteoarthrosis. Ann Rheum Dis 16:494e502

12.

Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW (1988) Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15:1833–1840PubMed

13.

Tüzün EH, Eker L, Aytar A, Daşkapan A, Bayramoğlu M (2005) Acceptability, reliability, validity and responsiveness of the Turkish version of WOMAC osteoarthritis index. Osteoarthr Cartil 13(1):28–33CrossRef

14.

Miller RG. (1966) Simultaneous statistical inference. McGraw-Hill: New York

15.

Xue J, Wang J, Liu Q et al (2013) Tumor necrosis factor-α induces ADAMTS-4 expression in human osteoarthritis chondrocytes. Mol Med Rep 8(6):1755–1760. https://doi.org/10.3892/mmr.2013.1729 CrossRefPubMed

16.

He Y, Zheng Q, Jiang M, Sun S, Christiansen TG, Kassem M, Karsdal MA, Bay-Jensen AC (2015) The effect of protease inhibitors on the induction of osteoarthritis-related biomarkers in bovine full-depth cartilage explants. PLoS One 10(4):e0122700. https://doi.org/10.1371/journal.pone.0122700 CrossRefPubMedPubMedCentral

17.

Moulharat N, Lesur C, Thomas M, Rolland-Valognes G, Pastoureau P, Anract P, de Ceuninck F, Sabatini M (2004) Effects of transforming growth factor-beta on aggrecanase production and proteoglycan degradation by human chondrocytes in vitro. Osteoarthr Cartil 12(4):296–305CrossRef

18.

Roberts S, Evans H, Wright K, van Niekerk L, Caterson B, Richardson JB, Kumar KHS, Kuiper JH (2015) ADAMTS-4 activity in synovial fluid as a biomarker of inflammation and effusion. Osteoarthr Cartil 23(9):1622–1626. https://doi.org/10.1016/j.joca.2015.05.006 CrossRef

19.

Peng S, Zheng Q, Zhang X, Dai L, Zhu J, Pi Y, Hu X, Cheng W, Zhou C, Sha Y, Ao Y (2013) Detection of ADAMTS-4 activity using a fluorogenic peptide-conjugated Au nanoparticle probe in human knee synovial fluid. ACS Appl Mater Interfaces 5(13):6089–6096. https://doi.org/10.1021/am400854z. CrossRefPubMed

20.

Zhang E, Yan X, Zhang M, Chang X, Bai Z, He Y, Yuan Z (2013) Aggrecanases in the human synovial fluid at different stages of osteoarthritis. Clin Rheumatol 32(6):797–803. https://doi.org/10.1007/s10067-013-2171-0 CrossRefPubMed

21.

Kamm JL, Nixon AJ, Witte TH (2010) Cytokine and catabolic enzyme expression in synovium, synovial fluid and articular cartilage of naurally osteoarthritic equine carpi. Equine Vet J 42(8):693–699. https://doi.org/10.1111/j.2042-3306.2010.00140.x CrossRefPubMedPubMedCentral

22.

Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T (2002) Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 46:2648e57CrossRef

23.

Wang P, Tortorella M, England K, Malfait AM, Thomas G, Arner EC, Pei D (2004) Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi network. J Biol Chem 279(15):15434–15440CrossRefPubMed

24.

Mayer G, Hamelin J, Asselin MC, Pasquato A, Marcinkiewicz E, Tang M, Tabibzadeh S, Seidah NG (2008) The regulated cell surface zymogen activation of the proprotein convertase PC5A directs the processing of its secretory substrates. J Biol Chem 283(4):2373–2384CrossRefPubMed

25.

Ariyoshi W, Takahashi N, Hida D, Knudson CB, Knudson W (2012) Mechanisms involved in enhancement of the expression and function of aggrecanases by hyaluronan oligosaccharides. Arthritis Rheum 64(1):187–197. https://doi.org/10.1002/art.33329 CrossRefPubMedPubMedCentral

26.

Kataoka Y, Ariyoshi W, Okinaga T, Kaneuji T, Mitsugi S, Takahashi T, Nishihara T (2013) Mechanisms involved in suppression of ADAMTS4 expression in synoviocytes by high molecular weight hyaluronic acid. Biochem Biophys Res Commun 432(4):580–585. https://doi.org/10.1016/j.bbrc.2013.02.043 CrossRefPubMed

27.

Erwin WM, Islam D, Inman RD, Fehlings MG, Tsui FWL (2011) Notochordal cells protect nucleus pulposus cells from degradation and apoptosis: implications for the mechanisms of intervertebral disc degeneration. Arthritis Res Ther 13(6):R215. https://doi.org/10.1186/ar3548 CrossRefPubMedPubMedCentral

28.

Korpetinou A, Skandalis SS, Labropoulou VT, Smirlaki G, Noulas A, Karamanos NK, Theocharis AD (2014) Serglycin: at the crossroad of inflammation and malignancy. Front Oncol 3:327. https://doi.org/10.3389/fonc.2013.00327 CrossRefPubMedPubMedCentral

29.

D’Ascola A, Scuruchi M, Avenoso A, Bruschetta G, Campo S, Mandraffino G, Campo GM (2018) Serglycin is involved in inflammatory response in articular mouse chondrocytes. Biochem Biophys Res Commun 499(3):506–512. https://doi.org/10.1016/j.bbrc.2018.03.178 CrossRefPubMed

30.

Toyama-Sorimachi N, Kitamura F, Habuchi H, Tobita Y, Kimata K, Miyasaka M (1997) Widespread expression of chondroitin sulfate type serglycins with CD44 binding ability in hematopoietic cells. J Biol Chem 272(42):26714–26719CrossRefPubMed

31.

Lord MS, Cheng B, Farrugia BL, McCarthy S, Whitelock JM (2017) Platelet factor 4 binds to vascular proteoglycans and controls both growth factor activities and platelet activation. J Biol Chem 292(10):4054–4063CrossRefPubMedPubMedCentral

32.

de Girolamo L, Kon E, Filardo G, Marmotti AG, Soler F, Peretti GM, Vannini F, Madry H, Chubinskaya S (2016) Regenerative approaches for the treatment of early OA. Knee Surg Sports Traumatol Arthrosc 24(6):1826–1835. https://doi.org/10.1007/s00167-016-4125-y CrossRefPubMed

Title: The role of increased synovial fluid A disintegrin and metalloproteinase with thrombospondin motifs4 and serglycin levels in osteoarthritis
Author: kenan ÖZLER
Publication date: 01-08-2019
Publisher: Springer London
Published in: Irish Journal of Medical Science (1971 -) / Issue 3/2019
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI: https://doi.org/10.1007/s11845-018-1945-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aim

Methods

Results

Please log in to get access to this content

Other articles of this Issue 3/2019

Transmission electron microscopy and histological analysis of the peridural membrane

Current concepts on bibliometrics: a brief review about impact factor, Eigenfactor score, CiteScore, SCImago Journal Rank, Source-Normalised Impact per Paper, H-index, and alternative metrics

An investigation into nature and extent of errors within the Irish Vital Statistics mortality database

Moving from peripheral blood to local uterine immunophenotype analysis in patients with poor reproductive history: pilot study of a novel technique

Limax Nd:YAG laser–assisted thoracoscopic resection of pulmonary metastases; a single centre’s initial experience

Parental awareness of newborn bloodspot screening in Ireland

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials